Aprepitant and Phenergan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Aprepitant (aprepitant) and Phenergan (promethazine hydrochloride). Common drug interactions include gallbladder disorder among females and cardiac failure among males.

The phase IV clinical study analyzes what interactions people have when they take Aprepitant and Phenergan. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Aprepitant?

Aprepitant has active ingredients of aprepitant. eHealthMe is studying from 6,992 Aprepitant users. Check the latest studies of Aprepitant.

What is Phenergan?

Phenergan has active ingredients of promethazine hydrochloride. It is often used in nausea. eHealthMe is studying from 25,312 Phenergan users. Check the latest studies of Phenergan.

On Jul, 16, 2026

22 people who take Aprepitant and Phenergan together, and have interactions are studied.

Aprepitant and Phenergan drug interactions.

What are the common drug interactions of Aprepitant and Phenergan, by gender? *:

female:

Gallbladder disorder
Procedural pain
Pyrexia (fever)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Cholecystitis (infection of gallbladder)
Asthenia (weakness)
Anaemia (lack of blood)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Hair colour changes

male:

Cardiac failure
Myelosuppression (a decrease in the production of blood cells)
Urinary retention (the inability to completely or partially empty the bladder)

What are the common drug interactions of Aprepitant and Phenergan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Pain
Pyrexia (fever)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Anaemia (lack of blood)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Small intestinal obstruction (blockage in small intestine)

40-49:

Abdominal pain upper
Biliary dyskinesia (motility disorder that affects the gallbladder and sphincter of oddi)
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Dyspepsia (indigestion)
Gallbladder disorder
Pain
Procedural pain
Alopecia (absence of hair from areas of the body)

50-59:

Cholecystitis (infection of gallbladder)
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Diarrhoea
Pain

60+:

Cardiac failure
Myelosuppression (a decrease in the production of blood cells)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Stomatitis (inflammation of mucous membrane of mouth)
Urinary retention (the inability to completely or partially empty the bladder)
Alopecia (absence of hair from areas of the body)
Hair colour changes
Hair disorder
Asthenia (weakness)
Blood urine present

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 27.27%
Breast Cancer: 5 people, 22.73%
Breast Cancer Female: 5 people, 22.73%
Nausea And Vomiting: 4 people, 18.18%
Blood Glucose Decreased: 3 people, 13.64%
Gastric Disorder (disease of stomach): 3 people, 13.64%
Urination - Excessive Volume: 3 people, 13.64%
Hormone Level Abnormal: 3 people, 13.64%
Hypoglycemia (low blood sugar): 3 people, 13.64%
Hypotension (abnormally low blood pressure): 3 people, 13.64%

* Approximation only. Some reports may have incomplete information.

Do you take Aprepitant and Phenergan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously